Jiangsu Key Laboratory of Zoonosis / Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, China
Abstract：Tuberculosis (TB) is a chronic disease caused by Mycobacterium tuberculosis complex(MTBC) and exhibits as respiratory infection in most cases. The low detection rate and high misdiagnosis rate from traditional methods result in TB spreading and treatment delaying. Therefore, there is an urgent need to find new TB biomarkers, which can be utilized to explore rapid, sensitive and efficient methods for TB diagnosis. Biomarkers of TB are also useful for tuberculosis treatment and some biomarkers can be used to develop TB vaccines. Biomarker research will help us understand TB pathogenesis. This review will summarize the biomarkers of tuberculosis and their applications.
[1] Jacobsen M, Mattow J, Repsilber D, et al. Novel strategies to identify biomarkers in tuberculosis[J]. Biol Chem, 2008, 389(5): 487-495. doi:10.1515/BC.2008.053 [2] Wu B, Huang C, Kato-Maeda M, et al. Messenger RNA expression of IL-8, FOXP3, and IL-12beta differentiates latent tuberculosis infection from disease[J]. J Immunol, 2007, 178: 3688-3694. doi:10.3844/ajavsp.2008.40.42 [3] Belkaid Y, Oldenhove G. Tuning microenvironments: induction of regulatory T cells by dendritic cells[J]. Immunity, 2008, 29: 362-371. doi:10.1016/j.immuni.2008.08.005 [4] Roberts T, Beyers N, Aguirre A, et al. Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels[J]. J Infect Dis, 2007, 195: 870-878. doi:10.1086/511277 [5] Hougardy JM, Place S, Hildebrand M, et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis[J]. Am J Respir Crit Care Med, 2007, 176: 409-416. doi:10.1164/rccm.200701-084OC [6] Aung H, Wu M, Johnson JL, et al. Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes[J]. Scand J Immunol, 2005, 61: 558-565. doi:10.1111/j.1365-3083.2005.01623.x [7] Djoba Siawaya JF, Bapela NB, Ronacher K, et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of antituberculosis chemotherapy response[J]. J Infect, 2008, 56: 340-347. doi:10.1016/j.jinf.2008.02.007 [8] Holodniy M. HIV-1 load quantitation: a 17-year perspective[J]. J Infect Dis, 2006, 194 (suppl 1): S38-44. doi:10.1086/505352 [9] Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test[J]. Clin Infect Dis, 1993, 17(6): 968-975 doi:10.1093/clinids/17.6.968 [10] CAST II investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction[J]. N Engl J Med, 1992, 327: 227-233. doi:10.1056/NEJM199207233270403 [11] Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework[J]. Clin Pharmacol Ther, 2001, 69: 89-95. doi:10.1056/NEJM199207233270403 [12] De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop[J]. Ctrl Clin Trials, 2001, 22: 485-502. doi:10.1016/S0197-2456(01)00153-2 [13] Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy[J]. Chest, 2007, 131(6): 1898-1906. doi:10.1378/chest.06-2471 [14] Andersen P, Doherty TM, Pai M, et al. The prognosis of latent tuberculosis: can disease be predicted?[J]. Trends Mol Med, 2007, 13(5): 175-182. doi:10.1016/j.molmed.2007.03.004 [15] Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse[J]. Lancet Infect Dis, 2009, 9(3): 162-172. doi:10.1016/S1473-3099(09)70042-8 [16] Chen YC, Chin CH, Liu SF, et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis[J]. Dis Markers, 2011, 31(2): 101-110. doi:10.3233/DMA-2011-0808 [17] Jacobsen M, Repsilber D, Gutschmidt A, et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis [J]. J Mol Med, 2007, 85(6): 613e21. doi:10.1007/s00109-007-0157-6 [18] Sartain MJ, Slayden RA, Singh KK, et al. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling[J]. Mol Cell Proteomics, 2006, 5(11): 2102e13. doi:10.1074/mcp.M600089-MCP200 [19] Kell DB. Systems biology, metabolic modelling and metabolomics in drug discovery and development[J]. Drug Discov Today, 2006, 11(23-24): 1085e92. doi:10.1016/j.drudis.2006.10.004 [20] Chee CB, Khinmar KW, Gan SH, et al. Tuberculosis treatment effect on T -cell interferon-γ responses to Mycobacterium tuberculosis -specific antigens[J]. Eur Respir J, 2010, 36: 355-361. doi:10.1183/09031936.00151309 [21] Sai Priya VH, Latha GS, Hasnain SE, et al. Enhanced T cell responsiveness to Mycobacterium bovis BCG r32-kDa Ag correlates with successful anti-tuberculosis treatment in humans[J]. Cytokine, 2010, 52: 190-193. doi:10.1016/j.cyto.2010.07.001 [22] Wassie L, Demissie A, Aseffa A, et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of Ethiopian TB patients and their contacts over time[J]. PLoS ONE, 2008, 3: e1522. doi:10.1371/journal.pone.0001522 [23] Bahk YY, Kim SA, Kim JS, et al. Antigens secreted from Mycobacterium tuberculosis : identification by proteomics approach and test for diagnostic marker[J]. Proteomics, 2004, 4(11): 3299e307. doi:10.1002/pmic.200400980 [24] Hill PC, Brookes RH, Fox A, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection[J]. PLoS Med, 2007, 4(6): e192. doi:10.1371/journal.pmed.0040192 [25] Sester M, Sotgiu G, Lange C, et al. Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis[J]. Eur Respir J, 2011, 37(1): 100-111. doi:10.1183/09031936.00114810 [26] Deng J, Bi L, Zhou L, et al. Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity[J]. Cell Rep, 2014, 9(6): 2317-2329. doi:10.1016/j.celrep.2014.11.023
2015, Vol. 31 
